Alterity Therapeutics Company Insiders
ATHE Stock | USD 3.28 0.21 6.02% |
Alterity Therapeutics employs about 10 people. The company is managed by 11 executives with a total tenure of roughly 24 years, averaging almost 2.0 years of service per executive, having 0.91 employees per reported executive. Evaluation of Alterity Therapeutics' management performance can provide insight into the firm performance.
Alterity |
Alterity Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Alterity Therapeutics' future performance. Based on our forecasts, it is anticipated that Alterity will maintain a workforce of about 10 employees by February 2025.Alterity Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.5266) % which means that it has lost $0.5266 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0447) %, meaning that it created substantial loss on money invested by shareholders. Alterity Therapeutics' management efficiency ratios could be used to measure how well Alterity Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 22, 2025, Return On Tangible Assets is expected to decline to -0.94. The current year's Return On Capital Employed is expected to grow to -1.55. At present, Alterity Therapeutics' Fixed Asset Turnover is projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.20, whereas Total Current Assets are forecasted to decline to about 18.7 M.The current year's Common Stock Shares Outstanding is expected to grow to about 4.4 B, whereas Net Loss is forecasted to decline to (13 M).
Alterity Therapeutics Workforce Comparison
Alterity Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 475. Alterity Therapeutics holds roughly 10.0 in number of employees claiming about 2.11% of equities under Health Care industry.
Alterity Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Alterity Therapeutics Price Series Summation is a cross summation of Alterity Therapeutics price series and its benchmark/peer.
Alterity Therapeutics Notable Stakeholders
An Alterity Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Alterity Therapeutics often face trade-offs trying to please all of them. Alterity Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Alterity Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Geoffrey BSc | CoFounder Chairman | Profile | |
Robert Cherny | Head Research | Profile | |
BBus CA | Company Sec | Profile | |
BSc BSc | CoFounder Chairman | Profile | |
Kathryn Andrews | Chief Officer | Profile | |
Steven Targum | Chief Advisor | Profile | |
CPA BCom | Chief Officer | Profile | |
Steven MD | Chief Advisor | Profile | |
BCom BSc | Chief Officer | Profile | |
David MD | Chief Officer | Profile | |
Rudolph Tanzi | Chief Board | Profile |
About Alterity Therapeutics Management Performance
The success or failure of an entity such as Alterity Therapeutics often depends on how effective the management is. Alterity Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Alterity management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Alterity management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.90) | (0.94) | |
Return On Capital Employed | (1.63) | (1.55) | |
Return On Assets | (1.14) | (1.20) | |
Return On Equity | (1.59) | (1.51) |
Please note, the presentation of Alterity Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alterity Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Alterity Therapeutics' management manipulating its earnings.
Alterity Therapeutics Workforce Analysis
Traditionally, organizations such as Alterity Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Alterity Therapeutics within its industry.Alterity Therapeutics Manpower Efficiency
Return on Alterity Therapeutics Manpower
Revenue Per Employee | 401.9K | |
Revenue Per Executive | 365.4K | |
Net Loss Per Employee | 1.9M | |
Net Loss Per Executive | 1.7M | |
Working Capital Per Employee | 1.4M | |
Working Capital Per Executive | 1.2M |
Complementary Tools for Alterity Stock analysis
When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |